In stably transfected Chinese hamster ovary cells, Cobicistat yielded an IC50 of 1.87±0.22 μmol/l for MATE1 transport of tetraethylammonium (3.6 μmol/l). In the same cell model, the IC50 for OCT2 transport of tetraethylammonium (3.6 μmol/l) was 24.0±4.6 μmol/l. In SARS-CoV-2-infected Vero E6 cells, Cobicistat treatment at 2.5 μM, 5 μM, or 10 μM decreased replication-competent virus in the supernatant, with a DMSO-only mixture used as the control. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cobicistat effects on MATE1 transport in transfected ovary cells
Cell-based study · stably transfected Chinese hamster ovary cells (OCT2 and MATE1) [1]
Model substrate inhibition studies were conducted in stably transfected Chinese hamster ovary cells (OCT2 and MATE1). Cobicistat most potently inhibited MATE1; IC50 = 1.87±0.22 μmol/l. Inhibition by compounds was studied by threefold serial dilution up to 100 μmol/l (cobicistat and dolutegravir).
Literature-Reported Treatment Conditions
- Treatment concentration
- threefold serial dilution up to 100 μmol/l
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: Cobicistat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Transporter inhibition assays (S42, S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)
MATE1: MATE1 — Materials and methods > Transporter inhibition assays (S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)
Cobicistat effects on OCT2 transport in transfected ovary cells
Cell-based study · stably transfected Chinese hamster ovary cells (OCT2 and MATE1) [1]
Model substrate inhibition studies were conducted in stably transfected Chinese hamster ovary cells (OCT2 and MATE1). Cobicistat showed weak inhibition of OCT2; IC50 = 24.0±4.6 μmol/l. Inhibition by compounds was studied by threefold serial dilution up to 100 μmol/l (cobicistat and dolutegravir).
Literature-Reported Treatment Conditions
- Treatment concentration
- threefold serial dilution up to 100 μmol/l
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: Cobicistat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Transporter inhibition assays (S42, S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)
OCT2: OCT2 — Materials and methods > Transporter inhibition assays (S43); Table 2 legend (S76); Table 2 (T2.h1, T2.r1, T2.r4)
Cobicistat effects on replication-competent virus in cell supernatants
Cell-based study · Vero E6 cells [2]
SARS-CoV-2-infected Vero E6 cells were treated with Cobicistat at 2.5 μM, 5 μM, or 10 μM. Cobicistat decreased replication-competent virus in supernatants collected at 24 h postinfection, with a DMSO-only mixture used as the control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2.5 μM, 5 μM, or 10 μM
- Exposure duration
- Two hours postinfection; Supernatants were collected at 24 h postinfection
- Method
- cobicistat was added
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: SARS-CoV-2 0.05 MOI. Compound effect isolated by the comparison: A 10 μM DMSO-only mixture was used as a control.
Methods and source locations
Compound reported in the paper: Cobicistat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > In silico and in vitro analyses identify cobicistat as a candidate inhibitor of SARS-CoV-2 replication. (S13); MATERIALS AND METHODS > Animal experiments. (S147); MATERIALS AND METHODS > Effect of cobicistat on replication-competent virus. (S156, S157, S158, S159, S163); MATERIALS AND METHODS > Syncytium formation assay. (S200)
plaques were manually counted after drying: plaques were manually counted after drying; comparator: A 10 μM DMSO-only mixture — RESULTS > In silico and in vitro analyses identify cobicistat as a candidate inhibitor of SARS-CoV-2 replication. (S13); MATERIALS AND METHODS > Effect of cobicistat on replication-competent virus. (S156, S157, S159, S163)